Details for Patent: 9,539,302

Which drugs does patent 9,539,302 protect, and when does it expire?

Patent 9,539,302 protects NOCTIVA and is included in one NDA.

This patent has seventy-one patent family members in nineteen countries.

Summary for Patent: 9,539,302

Title:	Safe desmopressin administration
Abstract:	Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome where desmopressin therapy is useful or where safe temporary suppression of urine production may lead to beneficial health effects or increased convenience in voiding control.
Inventor(s):	Fein; Seymour (New Canaan, CT)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	13/378,778
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,539,302
Patent Claim Types: see list of patent claims	Composition; Device;

Drugs Protected by US Patent 9,539,302

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acerus Pharms	NOCTIVA	desmopressin acetate	SPRAY, METERED;NASAL	201656-001	Mar 3, 2017		DISCN	Yes	No			Y
Acerus Pharms	NOCTIVA	desmopressin acetate	SPRAY, METERED;NASAL	201656-002	Mar 3, 2017		DISCN	Yes	No			Y

Foreign Priority and PCT Information for Patent: 9,539,302

PCT Information
PCT Filed	June 15, 2010	PCT Application Number:	PCT/US2010/038663
PCT Publication Date:	December 23, 2010	PCT Publication Number:	WO2010/147981

International Family Members for US Patent 9,539,302

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009330203
Australia	2010260211
Australia	2015261630
Australia	2016204306